Related references
Note: Only part of the references are listed.Chemotherapy rescues tumor-driven aberrant CD4+ T-cell differentiation and restores an activated polyfunctional helper phenotype
Zhi-Chun Ding et al.
BLOOD (2010)
Chemoimmunotherapy Reduces the Progression of Multiple Myeloma in a Mouse Model
Amir Sharabi et al.
CANCER PREVENTION RESEARCH (2010)
Higher intratumoral infiltrated Foxp3+Treg numbers and Foxp3+/CD8+ratio are associated with adverse prognosis in resectable gastric cancer
Zhengbin Shen et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2010)
Decreased Ratio of CD8+ T Cells to Regulatory T Cells Associated with Decreased Survival in Dogs with Osteosarcoma
B. J. Biller et al.
JOURNAL OF VETERINARY INTERNAL MEDICINE (2010)
Tumor-infiltrating lymphocytes, particularly the balance between CD8+ T cells and CCR4+ regulatory T cells, affect the survival of patients with oral squamous cell carcinoma
Yoshiko Watanabe et al.
ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTOLOGY (2010)
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
Michael A. Curran et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies
Raanan Berger et al.
CLINICAL CANCER RESEARCH (2008)
Regulatory T cells and tumour immunity - observations in mice and men
Awen Gallimore et al.
IMMUNOLOGY (2008)
Immune-potentiating effects chemotherapeutic drug of the cyclophosphamide
Sven Brode et al.
CRITICAL REVIEWS IN IMMUNOLOGY (2008)
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer
Junzo Hamanishi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer
Takeo Nomi et al.
CLINICAL CANCER RESEARCH (2007)
Elicitation of T cell responses to histologically unrelated tumors by immunization with the novel cancer-testis antigen, brother of the regulator of imprinted sites
Anahit Ghochikyan et al.
JOURNAL OF IMMUNOLOGY (2007)
Significance of B7-H1 overexpression in kidney cancer
R. Houston Thompson et al.
CLINICAL GENITOURINARY CANCER (2006)
Clinical roles of increased populations of Foxp3+CD4+ T cells in peripheral blood from advanced pancreatic cancer patients
Tetsuya Ikemoto et al.
PANCREAS (2006)
Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up
RH Thompson et al.
CANCER RESEARCH (2006)
The PD-1-PD-L pathway in immunological tolerance
T Okazaki et al.
TRENDS IN IMMUNOLOGY (2006)
Predominant expression of B7-H1 and its immunoregulatory roles in oral squamous cell carcinoma
F Tsushima et al.
ORAL ONCOLOGY (2006)
The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: Correlation with important high-risk prognostic factors
Hazem Ghebeh et al.
NEOPLASIA (2006)
Co-inhibitory role of T-cell-associated B7-H1 and B7-DC in the T-cell immune response
SK Seo et al.
IMMUNOLOGY LETTERS (2006)
Programmed death-1 (PD-1):PD-ligand 1 interactions inhibit TCR-mediated positive selection of thymocytes
ME Keir et al.
JOURNAL OF IMMUNOLOGY (2005)
Antibody-mediated signaling through PD-1 costimulates T cells and enhances CD28-dependent proliferation
ML del Rio et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2005)
CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms
RV Parry et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Cyclophosphamide decreases the number, percentage and the function of CD25+ CD4+ regulatory T cells, which suppress induction of contact hypersensitivity
Y Ikezawa et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2005)
Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer
Y Ohigashi et al.
CLINICAL CANCER RESEARCH (2005)
Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide
MEC Lutsiak et al.
BLOOD (2005)
Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma
LA Ormandy et al.
CANCER RESEARCH (2005)
PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells
C Blank et al.
CANCER RESEARCH (2004)
CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative
F Ghiringhelli et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2004)
B7-h1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression
J Konishi et al.
CLINICAL CANCER RESEARCH (2004)
Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target
RH Thompson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Foxp3 expressing CD4+CD25high regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells
M Viguier et al.
JOURNAL OF IMMUNOLOGY (2004)
Naturally arising CD4(+) regulatory T cells for immunologic self-tolerance and negative control of immune responses
S Sakaguchi
ANNUAL REVIEW OF IMMUNOLOGY (2004)
A push-pull approach to maximize vaccine efficacy: Abrogating suppression with an IL-13 inhibitor while augmenting help with granulocyte/macrophage colony-stimulating factor and CD40L
JD Ahlers et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25+ regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses
RPM Sutmuller et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2001)
PD-L2 is a second ligand for PD-I and inhibits T cell activation
Y Latchman et al.
NATURE IMMUNOLOGY (2001)
CD4+ T lymphocytes as a primary cellular target for BAT mAb stimulation
A Raiter et al.
INTERNATIONAL IMMUNOLOGY (2000)
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
GJ Freeman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Suppressor T cells: Rebirth, function and homeostasis
EM Shevach
CURRENT BIOLOGY (2000)
Immunologic self-tolerance maintained by CD25+CD4+ regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4
T Takahashi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Share Paper
